Components of Prostate Cancer PM​

Analyzes the genetic mutations and molecular characteristics of cancer cells to identify targetable alterations. This enables the identification of specific genetic mutations or biomarkers that can be targeted with therapies, improving treatment efficacy and reducing unnecessary exposure to ineffective treatments.

The use of specific molecules (biomarkers) in the body’s tissues, blood, or other fluids to help diagnose conditions, predict disease progression, and monitor treatment response. Facilitates early detection, helps in the selection of targeted therapies, and enables monitoring of disease progression and response to treatment.

Drugs or other substances designed to specifically interfere with cancer cell growth and progression at the molecular level. Offers a more focused approach to treatment by attacking specific genetic changes in cancer cells, leading to fewer side effects compared to traditional chemotherapy.

Treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. Can stimulate or restore the immune system’s ability to detect and destroy cancer cells, even those that have become resistant to other forms of treatment.

Drugs that inhibit the PARP (Poly ADP Ribose Polymerase) enzyme, which helps repair DNA damage in cells. Effective in cancers with certain DNA repair defects. Provides a targeted treatment option for patients with specific genetic mutations, such as BRCA1/2, improving survival in some cases of advanced prostate cancer.

Treatments that target the Prostate-Specific Membrane Antigen (PSMA), a protein overexpressed in prostate cancer cells. Allows for the precise delivery of radiation or drugs to cancer cells, minimizing damage to healthy tissue and improving treatment outcomes in advanced stages.

A form of targeted therapy that delivers radiation directly to cancer cells by using molecules that specifically bind to receptors on cancer cells.  Offers a novel treatment avenue for metastatic castration-resistant prostate cancer (mCRPC), showing promise in prolonging survival and improving quality of life.

Vaccines designed to prime the immune system to recognize and attack specific cancer cells based on the unique set of mutations present in an individual’s tumor. Provides a highly personalized approach to immunotherapy, potentially inducing long-lasting immunity against cancer cells and preventing recurrence.

A non-invasive test that detects cancer cells or fragments of tumor DNA circulating in the blood. Enables early detection of cancer or recurrence, monitoring of treatment response, and identification of mutations that may guide therapy selection without the need for invasive tissue biopsies.

Research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention. Provides access to the latest treatments and new drugs not yet available to the public, offering hope for improved outcomes through cutting-edge therapies.

Utilizing state-of-the-art imaging modalities, such as PSMA PET scans, to detect the precise location and extent of prostate cancer. Enhances the accuracy of diagnosis and staging, guides biopsy and treatment decisions, and improves the detection of cancer recurrence or metastasis.

Collaboration among specialists from various disciplines, including medical oncologists, urologists, radiologists, pathologists, and genetic counselors, to create a comprehensive care plan. Ensures a holistic approach to patient care, incorporating diverse expertise to tailor treatment strategies effectively and address the patient’s overall well-being.